Lesson plan

Telitacicept

Telitacicept (trade name Tai'ai) is a pharmaceutical drug used for the treatment of systemic lupus erythematosus (SLE). It is being developed by Yantai Rongchang Pharmaceuticals and RemeGen for various autoimmune diseases. In 2021, telitacicept was approved in China for the treatment of patients with active SLE. It is also being studied for the treatment of rheumatoid arthritis (RA) and multiple sclerosis (MS). Telitacicept is a fusion protein that combines a recombinant transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and a fragment of human immunoglobulin G (IgG).

Back to article

Article summary

Telitacicept (trade name Tai'ai) is a pharmaceutical drug used for the treatment of systemic lupus erythematosus (SLE). It is being developed by Yantai Rongchang Pharmaceuticals and RemeGen for various autoimmune diseases. In 2021, telitacicept was approved in China for the treatment of patients with active SLE. It is also being studied for the treatment of rheumatoid arthritis (RA) and multiple sclerosis (MS). Telitacicept is a fusion protein that combines a recombinant transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and a fragment of human immunoglobulin G (IgG).

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.